Zenas BioPharma, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
63.3M
on 2026-06-30, from 41.8M on 2024-09-30 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2025-10-08. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗
$200.0M
Jefferies, agreement of 2025-10-08. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Warrants
The 10-Q filed 2026-08-13 is not read yet.
Cash
11.4 quarters
$643.1M on 2026-06-30 ÷ $56.5M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-03-26 | Public offering | 5,000,000 | $20.00 | $100.0M | 424B5 ↗ |
| 2025-10-07 | Private placement | 6,261,893 | $19.00 | $120.0M | 8-K ↗ |
Also on file: $200.0M convertible notes, 2026-03-26 424B5 ↗ · $1K convertible notes, 2026-03-31 8-K ↗